Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Kiniksa Pharmaceuticals, Ltd.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered(3) | Proposed Maximum Offering Price Per Unit(1) | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||||||||
| Fees to Be Paid | Equity | Class A Common Shares, par value $$0.000273235 per share(1) | 457(c) | 28,682,554 | $ | 9.61 | $ | 275,639,343.94 | 0.0000927 | $ | 25,551.77 | |||||||||||||||||
| Total Offering Amounts | $ | 275,639,343.94 | ||||||||||||||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||||||||||||||
| Total Fee Offsets | $ | 25,551.77 | ||||||||||||||||||||||||||
| Net Fee Due | — | |||||||||||||||||||||||||||
| (1) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) of the Securities Act, and based upon the average of the high and low prices of the Class A common shares as reported on the Nasdaq Global Select Market on April 29, 2022. |
Table 2: Fee Offset Claims and Sources
| Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed(1) | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed(1) | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source(1) | |||||||||||||
| Rules 457(b) and 0-11(a)(2) | |||||||||||||||||||||||
| Fees Offset Claims | |||||||||||||||||||||||
| Fees Offset Sources | |||||||||||||||||||||||
| Rule 457(p) | |||||||||||||||||||||||
| Fee Offset Claims | Kiniksa Pharmaceuticals Ltd. | S-3 | 333-231910 | June 3, 2019 | $ | 25,551.77 | Equity | Class A Common Shares, par value $0.000273235 per share | 28,682,554 | $ 275,639,343.94 | |||||||||||||
| Fees Offset Sources | Kiniksa Pharmaceuticals Ltd. | S-3 | 333-231910 | June 3, 2019 | $ 53,118.37 | ||||||||||||||||||
| (1) | On June 3, 2019, the Registrant filed a Registration Statement on Form S-3 (File No. 333-231910), which became effective on June 10, 2019 (the “2019 Registration Statement”). Under the 2019 Registration Statement, the Registrant registered the resale of 28,882,977 Class A Common Shares by certain selling securityholders, of which 28,682,554 Class A common shares remain unsold (the “Unsold Securities”). Pursuant to Rule 457(p) promulgated under the Securities Act of 1933, as amended, the registration fee of $25,551.77 due for the Class A Common Shares registered under this registration statement is offset entirely by the registration fee previously paid by the registrant under the 2019 Registration Statement for the Unsold Securities. The offering that included the Unsold Securities under the 2019 Registration Statement has been terminated. |
